Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report issued on Saturday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright cut their price objective on Aethlon Medical from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, June 24th.

Aethlon Medical Stock Performance

Shares of NASDAQ AEMD opened at $0.36 on Friday. The firm has a 50 day moving average price of $0.39 and a two-hundred day moving average price of $0.81. The stock has a market cap of $4.98 million, a P/E ratio of -0.07 and a beta of 1.72. Aethlon Medical has a 52-week low of $0.24 and a 52-week high of $2.60.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.10. During the same period in the prior year, the business earned ($1.30) EPS. Analysts predict that Aethlon Medical will post -1.1 earnings per share for the current fiscal year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.